Self-Reported Eczema in Relation with Mortality from Cardiovascular Disease in Japanese: the Japan Collaborative Cohort Study.


Journal

Journal of atherosclerosis and thrombosis
ISSN: 1880-3873
Titre abrégé: J Atheroscler Thromb
Pays: Japan
ID NLM: 9506298

Informations de publication

Date de publication:
01 Sep 2019
Historique:
pubmed: 1 2 2019
medline: 15 2 2020
entrez: 1 2 2019
Statut: ppublish

Résumé

Previous studies suggested a positive association between eczema and cardiovascular disease (CVD), probably through enhanced systemic inflammation. However, several studies reported null findings about eczema and CVD, so the evidence is still controversial. We asked 85,099 participants (35,489 men and 49,610 women), aged 40 to 79 years, without a history of CVD or cancer at baseline between 1988 and 1990, to complete a lifestyle questionnaire, including information eczema frequency (seldom, sometimes or often). During the 6,389,818 person-years of follow-up, there were 1,174 deaths from coronary heart disease (CHD), 979 from heart failure, 366 from cardiac arrhythmia, 2,454 from total stroke, 1,357 from ischemic stroke, 1,013 from hemorrhagic stroke, and 201 from aortic aneurysm or dissection. The multivariable-adjusted model showed that individuals who "sometimes" or "often" had eczema had 0.82 (95%confidence interval (CI): 0.69-0.97) or 1.26 (95%CI: 1.01-1.56) times the risk of mortality from CHD, respectively, compared to those who "seldom" did. Individuals who "often" had 1.30 (95%CI: 1.05-1.61) times the risk of mortality from CHD, compared to those who "seldom or sometimes" did. There was no association of eczema with mortality from other CVD, or no interaction between eczema and sex or age, in relation to any CVD mortality risk. Self-reported frequent eczema was associated with increased risk of mortality from CHD, but not other major CVD, in a Japanese general population. Since steroid usage was not considered, future studies should include it as a potential confounding factor.

Identifiants

pubmed: 30700678
doi: 10.5551/jat.46383
pmc: PMC6753243
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

775-782

Références

Int J Epidemiol. 1999 Dec;28(6):1059-65
pubmed: 10661648
Ann Intern Med. 2004 Nov 16;141(10):764-70
pubmed: 15545676
Arthritis Rheum. 2005 Mar;52(3):722-32
pubmed: 15751097
Atherosclerosis. 2007 Sep;194(1):238-44
pubmed: 16963054
J Invest Dermatol. 2008 May;128(5):1207-11
pubmed: 18200064
Circulation. 2008 May 20;117(20):2577-9
pubmed: 18490534
J Eur Acad Dermatol Venereol. 2009 Nov;23(11):1311-5
pubmed: 19522710
Lancet. 2010 Jan 9;375(9709):132-40
pubmed: 20031199
J Invest Dermatol. 2010 Jul;130(7):1785-96
pubmed: 20445552
Can J Cardiol. 2011 Mar-Apr;27(2):174-82
pubmed: 21459266
Br J Dermatol. 2012 Jun;166(6):1301-8
pubmed: 22372948
J Epidemiol. 2013;23(3):227-32
pubmed: 23583921
J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:12-29
pubmed: 23845149
J Allergy Clin Immunol. 2013 Nov;132(5):1132-8
pubmed: 24094544
J Am Acad Dermatol. 2013 Dec;69(6):1014-24
pubmed: 24238156
Atherosclerosis. 2014 Jan;232(1):72-8
pubmed: 24401219
Ann Med. 2014 Mar;46(2):84-9
pubmed: 24460466
Eur Heart J. 2014 Jul 14;35(27):1782-91
pubmed: 24864079
Circulation. 2014 Sep 2;130(10):837-44
pubmed: 24970784
J Inflamm (Lond). 2014 Oct 11;11(1):29
pubmed: 25337037
J Allergy Clin Immunol. 2015 Mar;135(3):721-8.e6
pubmed: 25579484
Am J Med. 2015 Dec;128(12):1325-34.e2
pubmed: 26093174
Allergy. 2015 Oct;70(10):1300-8
pubmed: 26148129
PLoS One. 2016 Feb 24;11(2):e0149316
pubmed: 26910469
FEBS J. 2017 Feb;284(4):505-516
pubmed: 27650997
BMJ Open. 2016 Nov 11;6(11):e011870
pubmed: 27836869
J Invest Dermatol. 2017 May;137(5):1074-1081
pubmed: 28011146
Allergol Int. 2017 Apr;66(2):230-247
pubmed: 28209325
J Atheroscler Thromb. 2017 Oct 1;24(10):1039-1047
pubmed: 28302952
J Atheroscler Thromb. 2018 Feb 1;25(2):178-185
pubmed: 28740031
Heart. 2018 Jan;104(2):119-126
pubmed: 28847852
Rheumatol Int. 2018 Jan;38(1):37-50
pubmed: 29094181
J Am Acad Dermatol. 2018 Aug;79(2):345-352
pubmed: 29477740
J Atheroscler Thromb. 2018 Sep 1;25(9):846-984
pubmed: 30135334
J Am Heart Assoc. 2018 Oct 2;7(19):e007514
pubmed: 30371339
Circulation. 1994 Jan;89(1):109-15
pubmed: 8281635
N Engl J Med. 1999 Jan 14;340(2):115-26
pubmed: 9887164

Auteurs

Yoko Nishida (Y)

Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine.

Yasuhiko Kubota (Y)

Osaka Center for Cancer and Cardiovascular Disease Prevention.

Hiroyasu Iso (H)

Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine.

Akiko Tamakoshi (A)

Department of Public Health, Hokkaido University Faculty of Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH